focus -WSS

focus

author：entertainment 2025-09-30 00:10:14 - browse：133

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： CRISPR gene editing developments we’re watching in 2024

focus

WSS

How to protect coverage of PrEP

Severe heat forecast: Where scorching temperatures will persist over the next week

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Medicare drug price negotiation hasn't dried up venture capital

What STAT readers think about the FDA and patient advocacy

Medicare drug price negotiation hasn't dried up venture capital

leisure time

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Inside the culture of fear in the White House science office of Eric Lander

Heart attack and stroke risk calculators need revising

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Continuity nursing helped my family in our darkest PICU moments

Virtual care provider acquires bankrupt Pear's prescription apps

Wildfire smoke exposes gaps in outdoor worker protections

How a key Senate committee is planning to regulate PBMs

focus

SEC charges former device maker CEO with $41 million fraud

What STAT readers think about the FDA and patient advocacy

Virtual care provider acquires bankrupt Pear's prescription apps

Can sheer will power keep patients alive in their dying hours?

CRISPR gene editing developments we’re watching in 2024

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

focus

hotspot

hotspot

hotspot